Niki BioSolutions, Inc.
NIKI
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.24M
Close$
Share Statistics
| Market cap | $5.24 Million |
|---|---|
| Enterprise Value | $6.92 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -7216.56% |
|---|---|
| Return on Assets | -19.80% |
| Return on Invested Capital | -14.44% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.79 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.51 |
| Debt to Equity | 74.65 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Aptorum Group Ltd
1 employees
CEO: Chung Yuen Huen Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its w...